Philippe Moerman
Overview
Explore the profile of Philippe Moerman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
96
Citations
1866
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schoenen S, Delbecque K, Van Rompuy A, Marbaix E, Noel J, Delvenne P, et al.
Int J Gynecol Cancer
. 2022 Apr;
32(6):740-745.
PMID: 35487585
Objective: To evaluate the added value of a centralized pathology review of the diagnoses of gestational trophoblastic diseases by expert pathologists and its potential impact on clinical management in a...
2.
Milonas D, Steenkiste E, De Vos R, Moerman P, Lerut E, Joniau S
Curr Urol
. 2021 Jun;
15(2):126-128.
PMID: 34168533
The male Wolffian tumor is an extremely rare case in male patients. Here, we report a patient with such malignancy and successful radical surgical treatment at 15-year follow-up. The clinicopathological,...
3.
Van Nieuwenhuysen E, Busschaert P, Laenen A, Moerman P, Han S, Neven P, et al.
Neoplasia
. 2019 May;
21(6):582-590.
PMID: 31054497
Background: Low-grade serous ovarian cancer (LGSOC) is a rare subtype of epithelial ovarian carcinoma. Limited data regarding the molecular-genetic background exist beyond mutations in the RAS signaling pathway. There is...
4.
Baert T, Vermeesch J, Timmerman D, Vergote I, Moerman P
J Reprod Med
. 2018 Nov;
61(7-8):398-402.
PMID: 30408390
Background: Choriocarcinoma most frequently arises in a complete hydatidiform mole. Less common are cases following a normal pregnancy or a nonmolar abortion. Its occurrence after a partial hydatidiform mole is...
5.
Van Nieuwenhuysen E, Busschaert P, Neven P, Han S, Moerman P, Liontos M, et al.
Gynecol Oncol
. 2018 Sep;
151(1):61-68.
PMID: 30170975
Background: Ovarian germ cell tumors (OGCT) are rare gynecological neoplasms, mostly affecting children and young women. The underlying molecular genetic background of these tumors is poorly characterized. Methods: We analyzed...
6.
Gheysen W, Strybol D, Moerman P, Steylemans A, Corveleyn A, De Catte L, et al.
Clin Case Rep
. 2018 Aug;
6(8):1557-1560.
PMID: 30147904
Placental mesenchymal dysplasia (PMD) occurs in about 1 in 5000 pregnancies. The differential diagnosis between PMD and partial mole is difficult on ultrasound scan, and karyotyping plays a key role...
7.
Cuppens T, Moisse M, Depreeuw J, Annibali D, Colas E, Gil-Moreno A, et al.
Int J Cancer
. 2017 Oct;
142(6):1230-1243.
PMID: 29063609
Uterine leiomyosarcomas (uLMS) are rare, aggressive malignancies for which limited treatment options are available. To gain novel molecular insights into uLMS and identify potential novel therapeutic targets, we characterized 84...
8.
Michielsen K, Dresen R, Vanslembrouck R, De Keyzer F, Amant F, Mussen E, et al.
Eur J Cancer
. 2017 Jul;
83:88-98.
PMID: 28734146
Background: Despite excellent per-lesion performance for peritoneal staging, the additional clinical value of diffusion-weighted magnetic resonance imaging (DWI/MRI) compared to computed tomography (CT) remains to be established in ovarian cancer....
9.
Dewilde K, Moerman P, Leunen K, Amant F, Neven P, Vergote I
Gynecol Obstet Invest
. 2017 Jul;
83(1):65-69.
PMID: 28689208
Objective: Recent studies suggest that mucinous borderline ovarian tumors (MBOTs) belong to a high-risk group that is more likely to develop an invasive recurrence. The objective is to determine these...
10.
Cuppens T, Depreeuw J, Annibali D, Thomas D, Hermans E, Gomme E, et al.
Gynecol Oncol
. 2017 Jun;
146(3):538-545.
PMID: 28625393
Objective: Uterine sarcomas (US) and carcinosarcomas (CS) are rare, aggressive cancers. The lack of reliable preclinical models hampers the search for new treatment strategies and predictive biomarkers. To this end,...